Market Cap 4.58B
Revenue (ttm) 0.00
Net Income (ttm) -177.04M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 889,300
Avg Vol 1,357,052
Day's Range N/A - N/A
Shares Out 48.93M
Stochastic %K 81%
Beta 0.20
Analysts Strong Sell
Price Target $161.09

Company Profile

Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 neg...

Industry: Biotechnology
Sector: Healthcare
Phone: (763) 392-0123
Address:
2800 Campus Drive, Suite 140, Minneapolis, United States
DipinDipout
DipinDipout Aug. 23 at 5:57 PM
$CELC $CELC go away pumpers…this garbage about “interesting” opportunities is posted all over other boards, BLOCKED!
0 · Reply
LivermoresGhost
LivermoresGhost Aug. 22 at 8:31 PM
$QNC Cavitation Technologies has execute a binding Definitive Agreement for a buyout for this company. It is waiting for to close Alchemy Beverages deal, with EGS, it will close Monday! This will also add another 40c to the buyout price, makes a total buyout price 11.2c for 287% return. EGS has already show Proof of Funds. The tender will be open 45 days to get total share counts, and then another 30 days for investors to see. Buyout sp: 11.2c Current sp: 3.9c 287% Return on Investment. The tender offer for this will begin Monday! I ask all shareholders to watches this. Please share, and also tell your friends! https://x.com/cvatinfo_/status/2089350022311604396 $CELC $TRUMP.X $NAK $TMC
3 · Reply
LivermoresGhost
LivermoresGhost Aug. 22 at 7:07 PM
$CVAT Cavitation Technologies has execute a buyout for this company at 35 million $. This translate to 10.8c per share, you can finds this on the company SEC filing. The stock right now trades 3.9c, the buyout is for 10.8c. The buyer EGS, has already shown proof of funds, the Definitive Purchase Agreement has already been sign, and on Monday they will file the Tender Offer for submit your shares to the company. Buyout sp: 10.8c Current sp: 3.9c 270% Return on Investment, Tender will start Monday!!! https://feeds.issuerdirect.com/news-release.html?newsid=6453306525468884&symbol=CVAT $SBET $HYPE.X $FMCC $CELC
0 · Reply
HedgeFollow
HedgeFollow Aug. 22 at 6:28 PM
. 🔵 𝗗𝗢𝗨𝗕𝗟𝗘 𝗗𝗢𝗪𝗡𝘀 by 5-star Hedge Funds 🔵 𝘈𝘴 𝘱𝘦𝘳 𝘭𝘢𝘵𝘦𝘴𝘵 13𝘍 𝘧𝘪𝘭𝘪𝘯𝘨𝘴 𝘭𝘢𝘴𝘵 𝘸𝘦𝘦𝘬: 🔹Stephen Cohen (Point72) just 𝗱𝗼𝘂𝗯𝗹𝗲𝗱 his $PG position 🔹Bank of American 𝗱𝗼𝘂𝗯𝗹𝗲𝗱 $CELC stake 🔹Geode Capital 𝗱𝗼𝘂𝗯𝗹𝗲𝗱 $SBET (after holding steady for 3 quarters in a row) FYI, Stephen's 𝗽𝗼𝗿𝘁𝗳𝗼𝗹𝗶𝗼 𝗶𝘀 𝗨𝗣 184.40% in the past 3 years. Worth keeping an eye at what the outstanding funds do. Source: hedgefollow.com/stocks/SBET
0 · Reply
Erez1979
Erez1979 Aug. 22 at 5:51 PM
$CELC Put your money and relax.
0 · Reply
Merlintrader
Merlintrader Aug. 21 at 6:00 PM
$CELC Celcuity reported second-quarter results on August 13: no revenue in any period through June 30, a 78.9 million dollar net loss and 31.1 million of research and development. Liquidity looks enormous, 754.0 million in cash and short-term investments against 387.1 million three months earlier, but the same balance sheet carries 753.2 million of non-current convertible debt, and total liabilities of 841.0 million against total assets of 828.2 million leave stockholders equity at minus 12.8 million. The REVTORPYK launch is being funded with borrowed money, not with cash from the business. Free Biotech Catalyst Calendar on Merlintrader. https://www.merlintrader.com/celc-celcuity-inc/?utm_source=stocktwits&utm_medium=social&utm_campaign=giro-21ago2026
0 · Reply
HappyStockholder
HappyStockholder Aug. 21 at 3:30 PM
$CELC Clearly range bound until the next news announcement.
0 · Reply
Quantumup
Quantumup Aug. 21 at 3:11 PM
Needham🏁 $FTH Buy-$56 and said -- Targeting of the PI3K/AKT/mTOR signaling pathway in cancer has remained a challenge, with pharma focused on single node inhibitors. $CELC $RLAY NVS RHHBY AZN Needham added—Recently approved multi-node inhibitor Revtorpyk (CELC, Buy) has demonstrated clinical benefit in both mutant and WT PI3K patients, providing a clear POC. While we expect Revtorpyk's launch to help educate stakeholders on multi-node inhibition, its IV administration may limit expansion in earlier lines, especially in advanced mBC, where SOC is shifting to oral agents (e.g., oral SERDs). Piktor is a combination of orally available PI3Ka (serabelisib) and mTORC1/2 (sapanisertib) inhibitors, with early activity in endometrial cancer. Given its multi-node targeting and oral availability, we believe Piktor can act as a fast follower. We are initiating coverage of FTH with a Buy Rating and a $56 Target.
1 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Aug. 20 at 9:10 PM
$CELC sureee the analyst upgrades and ceo interview marinating over the weekend are totally irrelevant
1 · Reply
HappyStockholder
HappyStockholder Aug. 20 at 5:14 PM
$CELC Some posters like to cherry pick their data. Yesterday LABD was way down, and CELC barely moved. Price action here moves totally independent of LABD and, for that matter, LABU. CELC moves on company specific news. No news lately since the earnings report.
0 · Reply
Latest News on CELC
Celcuity price target raised to $175 from $165 at Guggenheim

2026-08-17T11:06:45.000Z - 7 days ago

Celcuity price target raised to $175 from $165 at Guggenheim


Celcuity reports Q2 EPS ($1.07), consensus ($1.16)

2026-08-16T14:11:38.000Z - 8 days ago

Celcuity reports Q2 EPS ($1.07), consensus ($1.16)


Celcuity price target lowered to $150 from $175 at Stifel

2026-08-16T13:44:29.000Z - 8 days ago

Celcuity price target lowered to $150 from $175 at Stifel


Celcuity price target lowered to $140 from $157 at Needham

2026-08-16T13:14:00.000Z - 8 days ago

Celcuity price target lowered to $140 from $157 at Needham


Celcuity Earnings Call Transcript: Q2 2026

Aug 13, 2026, 4:30 PM EDT - 10 days ago

Celcuity Earnings Call Transcript: Q2 2026


Celcuity Earnings release: Q2 2026

Aug 13, 2026, 4:30 PM EDT - 10 days ago

Celcuity Earnings release: Q2 2026


Celcuity Quarterly report: Q2 2026

Aug 13, 2026, 4:30 PM EDT - 10 days ago

Celcuity Quarterly report: Q2 2026


Short Report: Bears book profits in Celcuity

2026-07-26T14:50:08.000Z - 4 weeks ago

Short Report: Bears book profits in Celcuity

ARRY BOBS PVLA STAA


Celcuity falls -19.7%

2026-07-15T16:06:36.000Z - 5 weeks ago

Celcuity falls -19.7%


Celcuity falls -12.6%

2026-07-15T14:00:12.000Z - 5 weeks ago

Celcuity falls -12.6%


Celcuity price target raised to $177 from $160 at Citizens

2026-07-15T09:51:28.000Z - 5 weeks ago

Celcuity price target raised to $177 from $160 at Citizens


Celcuity Transcript: FDA announcement

Jul 14, 2026, 5:30 PM EDT - 5 weeks ago

Celcuity Transcript: FDA announcement


Celcuity Press release: FDA announcement

Jul 14, 2026, 5:30 PM EDT - 5 weeks ago

Celcuity Press release: FDA announcement


Celcuity Slides: FDA announcement

Jul 14, 2026, 5:30 PM EDT - 5 weeks ago

Celcuity Slides: FDA announcement


Celcuity announces FDA approval of Revtorpyk

2026-07-14T20:55:11.000Z - 5 weeks ago

Celcuity announces FDA approval of Revtorpyk


Celcuity Slides: Corporate presentation

Jul 14, 2026, 4:00 PM EDT - 5 weeks ago

Celcuity Slides: Corporate presentation


US FDA approves Celcuity's breast cancer drug

Jul 14, 2026, 3:29 PM EDT - 5 weeks ago

US FDA approves Celcuity's breast cancer drug


Celcuity Slides: FY 2026

Jun 10, 2026, 8:00 AM EDT - 2 months ago

Celcuity Slides: FY 2026


Celcuity prices $500M convertible senior note offering

2026-06-04T11:42:59.000Z - 2 months ago

Celcuity prices $500M convertible senior note offering


Celcuity price target lowered to $171 from $189 at Craig-Hallum

2026-06-03T15:14:03.000Z - 2 months ago

Celcuity price target lowered to $171 from $189 at Craig-Hallum


Celcuity price target lowered to $166 from $183 at Wells Fargo

2026-06-03T11:46:12.000Z - 2 months ago

Celcuity price target lowered to $166 from $183 at Wells Fargo


Celcuity falls -23.5%

2026-06-02T16:20:25.000Z - 2 months ago

Celcuity falls -23.5%


Celcuity Transcript: Study result

Jun 2, 2026, 8:00 AM EDT - 2 months ago

Celcuity Transcript: Study result


Celcuity Press release: Study result

Jun 2, 2026, 8:00 AM EDT - 2 months ago

Celcuity Press release: Study result


Celcuity Slides: Study result

Jun 2, 2026, 8:00 AM EDT - 2 months ago

Celcuity Slides: Study result


Celcuity To Participate in Upcoming Investor Conferences

May 28, 2026, 8:30 AM EDT - 3 months ago

Celcuity To Participate in Upcoming Investor Conferences


Celcuity Earnings Call Transcript: Q1 2026

May 14, 2026, 4:30 PM EDT - 3 months ago

Celcuity Earnings Call Transcript: Q1 2026


Celcuity Earnings release: Q1 2026

May 14, 2026, 4:30 PM EDT - 3 months ago

Celcuity Earnings release: Q1 2026


Celcuity Quarterly report: Q1 2026

May 14, 2026, 4:30 PM EDT - 3 months ago

Celcuity Quarterly report: Q1 2026


Celcuity Proxy statement: Proxy filing

Apr 2, 2026, 8:00 AM EDT - 5 months ago

Celcuity Proxy statement: Proxy filing


Celcuity Proxy statement: Proxy filing

Apr 2, 2026, 8:00 AM EDT - 5 months ago

Celcuity Proxy statement: Proxy filing


Celcuity Earnings Call Transcript: Q4 2025

Mar 25, 2026, 4:30 PM EDT - 5 months ago

Celcuity Earnings Call Transcript: Q4 2025


Celcuity Annual report: Q4 2025

Mar 25, 2026, 4:30 PM EDT - 5 months ago

Celcuity Annual report: Q4 2025


Celcuity Earnings release: Q4 2025

Mar 25, 2026, 4:30 PM EDT - 5 months ago

Celcuity Earnings release: Q4 2025


Celcuity Transcript: Leerink Global Healthcare Conference 2026

Mar 10, 2026, 2:20 PM EDT - 5 months ago

Celcuity Transcript: Leerink Global Healthcare Conference 2026


Celcuity Transcript: TD Cowen 46th Annual Health Care Conference

Mar 4, 2026, 10:30 AM EST - 6 months ago

Celcuity Transcript: TD Cowen 46th Annual Health Care Conference


Celcuity Appoints Charles Romp to its Board of Directors

Feb 12, 2026, 4:05 PM EST - 6 months ago

Celcuity Appoints Charles Romp to its Board of Directors


Celcuity Earnings Call Transcript: Q3 2025

Nov 12, 2025, 4:30 PM EST - 10 months ago

Celcuity Earnings Call Transcript: Q3 2025


Celcuity Quarterly report: Q3 2025

Nov 12, 2025, 4:30 PM EST - 10 months ago

Celcuity Quarterly report: Q3 2025


Celcuity Earnings release: Q3 2025

Nov 12, 2025, 4:30 PM EST - 10 months ago

Celcuity Earnings release: Q3 2025


Celcuity Transcript: Stifel 2025 Healthcare Conference

Nov 11, 2025, 10:00 AM EST - 10 months ago

Celcuity Transcript: Stifel 2025 Healthcare Conference


Celcuity Transcript: Study Result

Oct 20, 2025, 8:00 AM EDT - 11 months ago

Celcuity Transcript: Study Result


Celcuity Press release: Study Result

Oct 20, 2025, 8:00 AM EDT - 11 months ago

Celcuity Press release: Study Result


Celcuity Slides: Study Result

Oct 20, 2025, 8:00 AM EDT - 11 months ago

Celcuity Slides: Study Result


Celcuity Slides: Corporate Presentation

Oct 16, 2025, 7:00 AM EDT - 11 months ago

Celcuity Slides: Corporate Presentation


Celcuity Earnings Call Transcript: Q2 2025

Aug 14, 2025, 4:30 PM EDT - 1 year ago

Celcuity Earnings Call Transcript: Q2 2025


Celcuity Earnings release: Q2 2025

Aug 14, 2025, 4:30 PM EDT - 1 year ago

Celcuity Earnings release: Q2 2025


Celcuity Quarterly report: Q2 2025

Aug 14, 2025, 4:30 PM EDT - 1 year ago

Celcuity Quarterly report: Q2 2025


DipinDipout
DipinDipout Aug. 23 at 5:57 PM
$CELC $CELC go away pumpers…this garbage about “interesting” opportunities is posted all over other boards, BLOCKED!
0 · Reply
LivermoresGhost
LivermoresGhost Aug. 22 at 8:31 PM
$QNC Cavitation Technologies has execute a binding Definitive Agreement for a buyout for this company. It is waiting for to close Alchemy Beverages deal, with EGS, it will close Monday! This will also add another 40c to the buyout price, makes a total buyout price 11.2c for 287% return. EGS has already show Proof of Funds. The tender will be open 45 days to get total share counts, and then another 30 days for investors to see. Buyout sp: 11.2c Current sp: 3.9c 287% Return on Investment. The tender offer for this will begin Monday! I ask all shareholders to watches this. Please share, and also tell your friends! https://x.com/cvatinfo_/status/2089350022311604396 $CELC $TRUMP.X $NAK $TMC
3 · Reply
LivermoresGhost
LivermoresGhost Aug. 22 at 7:07 PM
$CVAT Cavitation Technologies has execute a buyout for this company at 35 million $. This translate to 10.8c per share, you can finds this on the company SEC filing. The stock right now trades 3.9c, the buyout is for 10.8c. The buyer EGS, has already shown proof of funds, the Definitive Purchase Agreement has already been sign, and on Monday they will file the Tender Offer for submit your shares to the company. Buyout sp: 10.8c Current sp: 3.9c 270% Return on Investment, Tender will start Monday!!! https://feeds.issuerdirect.com/news-release.html?newsid=6453306525468884&symbol=CVAT $SBET $HYPE.X $FMCC $CELC
0 · Reply
HedgeFollow
HedgeFollow Aug. 22 at 6:28 PM
. 🔵 𝗗𝗢𝗨𝗕𝗟𝗘 𝗗𝗢𝗪𝗡𝘀 by 5-star Hedge Funds 🔵 𝘈𝘴 𝘱𝘦𝘳 𝘭𝘢𝘵𝘦𝘴𝘵 13𝘍 𝘧𝘪𝘭𝘪𝘯𝘨𝘴 𝘭𝘢𝘴𝘵 𝘸𝘦𝘦𝘬: 🔹Stephen Cohen (Point72) just 𝗱𝗼𝘂𝗯𝗹𝗲𝗱 his $PG position 🔹Bank of American 𝗱𝗼𝘂𝗯𝗹𝗲𝗱 $CELC stake 🔹Geode Capital 𝗱𝗼𝘂𝗯𝗹𝗲𝗱 $SBET (after holding steady for 3 quarters in a row) FYI, Stephen's 𝗽𝗼𝗿𝘁𝗳𝗼𝗹𝗶𝗼 𝗶𝘀 𝗨𝗣 184.40% in the past 3 years. Worth keeping an eye at what the outstanding funds do. Source: hedgefollow.com/stocks/SBET
0 · Reply
Erez1979
Erez1979 Aug. 22 at 5:51 PM
$CELC Put your money and relax.
0 · Reply
Merlintrader
Merlintrader Aug. 21 at 6:00 PM
$CELC Celcuity reported second-quarter results on August 13: no revenue in any period through June 30, a 78.9 million dollar net loss and 31.1 million of research and development. Liquidity looks enormous, 754.0 million in cash and short-term investments against 387.1 million three months earlier, but the same balance sheet carries 753.2 million of non-current convertible debt, and total liabilities of 841.0 million against total assets of 828.2 million leave stockholders equity at minus 12.8 million. The REVTORPYK launch is being funded with borrowed money, not with cash from the business. Free Biotech Catalyst Calendar on Merlintrader. https://www.merlintrader.com/celc-celcuity-inc/?utm_source=stocktwits&utm_medium=social&utm_campaign=giro-21ago2026
0 · Reply
HappyStockholder
HappyStockholder Aug. 21 at 3:30 PM
$CELC Clearly range bound until the next news announcement.
0 · Reply
Quantumup
Quantumup Aug. 21 at 3:11 PM
Needham🏁 $FTH Buy-$56 and said -- Targeting of the PI3K/AKT/mTOR signaling pathway in cancer has remained a challenge, with pharma focused on single node inhibitors. $CELC $RLAY NVS RHHBY AZN Needham added—Recently approved multi-node inhibitor Revtorpyk (CELC, Buy) has demonstrated clinical benefit in both mutant and WT PI3K patients, providing a clear POC. While we expect Revtorpyk's launch to help educate stakeholders on multi-node inhibition, its IV administration may limit expansion in earlier lines, especially in advanced mBC, where SOC is shifting to oral agents (e.g., oral SERDs). Piktor is a combination of orally available PI3Ka (serabelisib) and mTORC1/2 (sapanisertib) inhibitors, with early activity in endometrial cancer. Given its multi-node targeting and oral availability, we believe Piktor can act as a fast follower. We are initiating coverage of FTH with a Buy Rating and a $56 Target.
1 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Aug. 20 at 9:10 PM
$CELC sureee the analyst upgrades and ceo interview marinating over the weekend are totally irrelevant
1 · Reply
HappyStockholder
HappyStockholder Aug. 20 at 5:14 PM
$CELC Some posters like to cherry pick their data. Yesterday LABD was way down, and CELC barely moved. Price action here moves totally independent of LABD and, for that matter, LABU. CELC moves on company specific news. No news lately since the earnings report.
0 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Aug. 20 at 2:58 PM
$CELC as soon as I see LABD up I know my bios are crashing commensurately
1 · Reply
TheTarkioTrader
TheTarkioTrader Aug. 20 at 10:35 AM
$CELC At this stage, with FDA approval behind it, NCCN Category 1 status, commercialization around the corner, and a pipeline that could expand the opportunity substantially, the 37% short position looks increasingly aggressive. Actually insane
1 · Reply
TheTarkioTrader
TheTarkioTrader Aug. 19 at 9:24 PM
$CELC new institutions * Aug. 18 — Fulcrum Asset Management: 2,808 shares * Aug. 17 — Jefferies Financial Group: 89,234 shares * Aug. 17 — CI Private Wealth: 12,015 shares
0 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Aug. 19 at 12:41 PM
0 · Reply
TheTarkioTrader
TheTarkioTrader Aug. 19 at 11:04 AM
$CELC remember stick with this loser
0 · Reply
DipinDipout
DipinDipout Aug. 19 at 10:42 AM
$CELC **worth exploring** = **worth blocking**
0 · Reply
DipinDipout
DipinDipout Aug. 19 at 10:40 AM
$CELC go away pumpers…this garbage about “interesting” opportunities is posted all over other boards, BLOCKED!
0 · Reply
MurrayKummer360
MurrayKummer360 Aug. 19 at 9:09 AM
$KODK $CELC $NTDOY $IPO Kodak remains execution-dependent around imaging and specialty businesses, Celcuity remains focused on precision oncology, Nintendo benefits from gaming hardware and software demand, and IPO remains highly speculative. I'm watching execution, clinical progress, game launches, and liquidity.
0 · Reply
CDSTrading
CDSTrading Aug. 19 at 8:58 AM
$KODK $CELC $NTDOY $IPO Kodak remains execution-dependent around imaging and specialty businesses, Celcuity remains focused on precision oncology, Nintendo benefits from gaming hardware and software demand, and IPO remains highly speculative. I'm watching execution, clinical progress, game launches, and liquidity.
0 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Aug. 18 at 10:12 PM
0 · Reply
TheTarkioTrader
TheTarkioTrader Aug. 18 at 8:47 PM
$CELC CELC Insider Update — August 18 Two key Celcuity insiders reported significant increases in their equity positions: CEO Brian F. Sullivan: acquired 80,000 shares at $0, bringing his direct ownership to approximately 1.45 million shares. CFO Vicky Hahne: acquired 16,000 shares at $0 through vesting and also received 10,000 performance stock units tied to CELC achieving specified stock-price thresholds. Neither transaction was an open-market cash purchase, so I wouldn’t call these traditional insider buys. But the important takeaway is that both the CEO and CFO increased their equity exposure to CELC, and the CFO’s performance awards are specifically tied to the stock reaching higher price levels. That’s certainly constructive insider alignment, especially with both top executives increasing their exposure at this point in the company’s development.
0 · Reply
TheTarkioTrader
TheTarkioTrader Aug. 18 at 6:36 PM
$CELC new institutional holders * Jefferies: 89,234 shares * CI Private Wealth: 12,015 * Seven Fleet: 16,252 * Fulcrum Asset Management: 2,808
0 · Reply